HOME >> BIOLOGY >> NEWS
Studies of rare blood syndrome yield novel route to cancer

By carefully studying why a rare blood disorder responds to the anti-cancer drug Gleevec, researchers have discovered an entirely new mechanism that generates cancer-causing genes.

The study, published in the March 27, 2003, issue of the New England Journal of Medicine, shows that Gleevec is an effective treatment for hypereosinophilic syndrome (HES), a blood disorder that is nearly always fatal. According to the researchers, their studies suggest that HES should be reclassified by the World Health Organization from its current "gray-area" status as a "syndrome" to a form of cancer.

Senior authors of the article were D. Gary Gilliland, a Howard Hughes Medical Institute investigator at Brigham and Women's Hospital and Harvard Medical School, and Richard Stone at the Dana-Farber Cancer Institute (DFCI). Joint first authors on the paper were Jan Cools, a postdoctoral fellow in Gilliland's laboratory, and Daniel DeAngelo, who is also at DFCI and an instructor at Harvard Medical School.

HES is caused by overproliferation of a type of white blood cells called eosinophils. Physicians treat the syndrome with a combination of drugs and chemotherapy, said Gilliland, but eventually, the assault of eosinophils damages major organs, and causes the heart or lungs to fail, and ultimately results in death of most patients.

Recently, however, hints that the disorder might respond to Gleevec began to crop up in the medical literature. "There was a report of a single case of an HES patient treated with Gleevec and had what was described as a miraculous response," said Gilliland. "This anecdotal report was substantiated by a group of investigators that reported successful treatment in 4 of 5 additional HES patients, reported in the The Lancet (a British medical journal) last year.

Gleevec works by inhibiting enzymes called tyrosine kinases. When the activity of
'"/>

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
26-Mar-2003


Page: 1 2 3 4

Related biology news :

1. Monkey business: Studies show tiny callimicos have unusual characteristics
2. Studies show success of Mectizan partnerships
3. Studies offer new insight into HIV vaccine development
4. Studies suggest brain injury results from developmental exposure to alcohol, anesthesia, and lead
5. Studies show preventive value of food supplements
6. Studies probe rapid evolution of Chinese tallow trees
7. Studies dispute ultraviolet effect on amphibian population declines
8. Studies of spiders silk reveal unusual strength
9. Studies of genes in mice and common worm may accelerate research on blood diseases, cancers
10. Studies offer data on potential impact of Reminyl on caregiver burden in Alzheimers disease
11. Studies: Floyd, other major hurricanes of 99 caused significant changes in nations largest lagoonal estuary

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/26/2019)... ... July 25, 2019 , ... ... the first mixed reality headsets to include a new generation eye tracker with ... in Los Angeles, California (July 30 - August 1). SIGGRAPH attendees will ...
(Date:7/23/2019)... Conn. (PRWEB) , ... July 23, 2019 , ... ... that provides personalized, easy-to-understand, web-based genetic counseling, today announced that the company has ... related to MUTYH-associated polyposis (MAP), familial hypercholesterolemia (FH), and Parkinson’s disease. , The ...
(Date:7/23/2019)... ... July 23, 2019 , ... NanoFUSE is pleased ... strip indicated for spine and orthopedic use. Bioactive glass is a calcium phosphate ... been clinically-proven in orthopedics for over 30 years and now NanoFUSE Biologics has ...
Breaking Biology News(10 mins):
(Date:8/6/2019)... ... August 06, 2019 , ... The ... the launch of a community project that will engage middle and early high ... project, entitled “A Youth-Led Citizen Science Network for Community Environmental Assessment.” Collaborative partners ...
(Date:7/19/2019)... (PRWEB) , ... July 18, 2019 , ... ... Instrumente) announced their investment to enlarge their current piezo motion facilities in Lederhose, ... offer 3 floors for multilayer piezo ceramic assembly production in addition to general ...
(Date:7/11/2019)... VEGAS (PRWEB) , ... July 11, 2019 , ... At ... R3 provided complimentary regenerative therapies to eight military Veterans under the R3 Heroes Program. ... being complimentary. , The R3 Heroes Program allow anyone to nominate a military Veteran, ...
(Date:6/18/2019)... N.J. (PRWEB) , ... June 17, 2019 , ... ... announced that they have entered into an agreement for production and manufacturing of ... for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for ...
Breaking Biology Technology:
Cached News: